Innovations in Depression Diagnosis and Treatment: A Review of Biological, Cognitive, and Psychosocial Advances.
Current topics in medicinal chemistry May 21, 2026 Guizhen Lyu, Dongbing Li
Depression affects over 300 million people worldwide and is a leading cause of disability. This review synthesizes recent advances in understanding depression across biological, cognitive, and psychosocial domains, highlighting innovations in diagnosis, pathophysiology, and treatment. It explores distinctions between major depressive disorder and bipolar depression, emphasizing biomarkers and neuroimaging to reduce misdiagnosis. Special attention is given to under-researched subtypes like postpartum, inflammation-related, and adolescent depression. Pathophysiological insights include dysregulated neurotransmitter systems, neuroinflammation, and disrupted neural connectivity, with genetic-environment interactions underscoring personalized approaches. Advances in treatment range from FDA-approved neurosteroid therapies for postpartum depression to psychedelic-assisted psychotherapy for treatment-resistant cases, advocating for precision psychiatry and interdisciplinary models to reduce healthcare disparities.